DMAA Files 8-K with Letter of Intent
Ticker: DMAA · Form: 8-K · Filed: Apr 8, 2026 · CIK: 0002028614
| Field | Detail |
|---|---|
| Company | Drugs Made In America Acquisition Corp. (DMAA) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2026 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, letter-of-intent, 8-k
TL;DR
DMAA signed an LOI for an acquisition - big moves ahead!
AI Summary
Drugs Made In America Acquisition Corp. (DMAA) filed an 8-K on April 8, 2026, disclosing a Letter of Intent (LOI) related to a potential acquisition. The filing includes Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits), with the LOI attached as Exhibit 10.1.
Why It Matters
This filing indicates that Drugs Made In America Acquisition Corp. is actively pursuing an acquisition, which could significantly alter its business operations and future prospects.
Risk Assessment
Risk Level: medium — The filing indicates a potential acquisition, which carries inherent risks and uncertainties until finalized.
Key Players & Entities
- Drugs Made In America Acquisition Corp. (company) — Filer
- 0002028614 (company) — CIK
- 2026-04-08 (date) — Filing Date
- EX-10.1 (document) — Letter of Intent Exhibit
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report other events (Item 8.01) and financial statements/exhibits (Item 9.01), specifically disclosing a Letter of Intent related to a potential acquisition.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on April 8, 2026, at 09:00:33.
What specific exhibit is attached to this filing that is of interest?
Exhibit 10.1, a Letter of Intent, is attached to this filing.
What is the CIK number for Drugs Made In America Acquisition Corp.?
The CIK number for Drugs Made In America Acquisition Corp. is 0002028614.
What is the SIC code listed for this company?
The SIC code listed for this company is 6770, which falls under Blank Checks.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 8, 2026 regarding Drugs Made In America Acquisition Corp. (DMAA).